Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences
Pharmaceuticals · 08.08.2025 · 18 (8) · 1170
DOI: 10.3390/ph18081170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.08.2025. Verfasst von April Kennedy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SickKids Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background/Objectives: Medication discontinuation attributable to adverse drug reactions (ADRs) and/or inefficacy remains a concern of psychotropic medications among children and adolescents. Pharmacogenetic (PGx) testing has been proposed to individualize treatment, although its utility remains uncertain. We retrospectively evaluated whether PGx testing of two key metabolism genes (i.e., CYP2C19 and CYP2D6) explains reported episodes of ADRs and treatment inefficacy experienced by children and adolescents with diverse mental health conditions.
Methods
PGx testing of CYP2C19 and CYP2D6 was conducted for 100 participants before, during, or after the use of psychotropic medication(s) that have clinical practice guidelines supporting PGx-guided dosing. The theoretical impact on medication dosing was reviewed in the context of clinical guidelines. We then evaluated whether the PGx-inferred metabolizer phenotype was consistent with reported ADR and/or treatment inefficacy.
Results
If PGx testing had been performed before the start of treatment, 43% (35/82) of participants would have been recommended dose adjustments or alternative therapy of at least one medication. PGx test results corroborated 8% (6/76) of ADR events and 3% (2/61) of inefficacies. However, no single participant had all prior reported ADRs or inefficacies explained by the results of CYP2C19 nor CYP2D6 testing.
Conclusions
Reactive testing of CYP2C19 and CYP2D6 provided limited insight into isolated incidents of psychotropic medication intolerance in this population. No individual’s PGx test results explained all episodes of ADR or suboptimal response. Variation in drug metabolism genes alone does not provide an explanation for multiple episodes of inefficacy or adverse reaction. In the setting of child and adolescent psychiatry, PGx testing is best suited for preemptive use to complement clinical decision making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
- Department of Paediatrics, University of Toronto, Toronto, ON M5G 1X8, Canada.
- Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
ORCID-Profile: April Kennedy, Sierra Scodellaro, Ruud H J Verstegen
Förderung
- SickKids Foundation
Zitieren
APA
Kennedy, A., Scodellaro, S., Verstegen, R. H. J., & Cohn, I. (2025). Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences. Pharmaceuticals, 18(8), 1170. https://doi.org/10.3390/ph18081170
Vancouver
Kennedy A, Scodellaro S, Verstegen RHJ, Cohn I. Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences. Pharmaceuticals. 2025;18(8):1170. doi:10.3390/ph18081170
BibTeX
@article{Kennedy2025,
author = {Kennedy, April and Scodellaro, Sierra and Verstegen, Ruud H J and Cohn, Iris},
title = {Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {8},
pages = {1170},
doi = {10.3390/ph18081170}
}
EUVIMED